Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance

Histone deacetylase inhibitors (HDACi) have shown promising activity against hematological malignancies in clinical trials and have led to the approval of vorinostat for the treatment of cutaneous T-cell lymphoma. However, de novo or acquired resistance to HDACi therapy is inevitable, and their mole...

Descripción completa

Detalles Bibliográficos
Autores principales: Dupéré-Richer, D, Kinal, M, Ménasché, V, Nielsen, T H, del Rincon, S, Pettersson, F, Miller, W H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734816/
https://www.ncbi.nlm.nih.gov/pubmed/23392174
http://dx.doi.org/10.1038/cddis.2012.210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734816/
https://www.ncbi.nlm.nih.gov/pubmed/23392174
http://dx.doi.org/10.1038/cddis.2012.210

Ejemplares similares